DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Guggenheim Securities Initiates Coverage On Ligand Pharmaceuticals with Neutral Rating

Guggenheim Securities analyst Dana Flanders initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Neutral rating.

Benzinga · 03/10/2020 08:56

Guggenheim Securities analyst Dana Flanders initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Neutral rating.